Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11473137 | 0.85 | IDO1 (0.45) | HTR2ACCKBRHRH1IDO1AKT1 | |
| SCHEMBL29558888 | 0.85 | IDO1 (0.45) | HTR2ACCKBRHRH1IDO1AKT1 | |
| SCHEMBL19149276 | 0.82 | HTR2A (0.45) | HTR2ACCKBRHRH1IDO1AKT1 | |
| SCHEMBL3693863 | 0.81 | BCHE (0.44) | HTR2ACCKBRRETHTR2CHRH1 | |
| SCHEMBL12141050 | 0.80 | CCKBR (0.42) | HTR2ACCKBRHTR2CHRH2OPRM1 | |
| SCHEMBL550107 | 0.80 | CCKBR (0.42) | CCKBRAKT1HRH2OPRM1HTR2B | |
| SCHEMBL12013752 | 0.80 | CCKBR (0.42) | HTR2ACCKBRHTR2CHRH2OPRM1 | |
| SCHEMBL6630128 | 0.80 | CCKBR (0.42) | CCKBRMEN1KMT2AAKT1HRH2 | |
| SCHEMBL1118519 | 0.80 | CCKBR (0.42) | HTR2ACCKBRHTR2CHRH2OPRM1 | |
| SCHEMBL5536820 | 0.80 | CCKBR (0.42) | CCKBRMEN1KMT2AAKT1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117624179-A | 3- (amino) methylene indoline derivative and preparation method and application thereof | 徐诺药业(南京)有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117624179-A | 3- (amino) methylene indoline derivative and preparation method and application thereof | 徐诺药业(南京)有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | BOEHRINGER MARKUS (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| CN-101304989-A | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor XA | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | CN | disclosed |
| EP-1948639-A2 | NOVEL CARBOCYCLIC FUSED CYCLIC AMINES | F. Hoffmann-la Roche AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054453-A2 | CARBOCYCLIC FUSED CYCLIC AMINES AS INHIBITORS OF THE COAGULATION FACTOR XA | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112012-A1 | Carbocyclic fused cyclic amines | F12, F11, F2 | HTR2A 1196/4885CCKBR 119/4885RET 2150/4885 |
| US-20120122854-A1 | Carbocyclic Fused Cyclic Amines | F12, F11, F2 | HTR2A 1196/4885CCKBR 119/4885RET 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.